CLEMSON — When Leland Dunwoodie, an undergraduate biochemistry student at Clemson University, approached his professor about wanting to start research on “some human stuff” in the spring of 2016, he didn’t imagine it would lead to the discovery of 22 genes that are implicated in glioblastoma, the most aggressive type of brain cancer.
“I definitely didn’t come to Clemson thinking about brain cancer research,” said Dunwoodie. “I was working on a project with grapes and other plants. I told Dr. (Alex) Feltus that I wanted to do some human stuff, and he said, ‘That’s cool – pick an organ.’ ”
After consulting with his family in Milton, Georgia — should he study the brain or the heart? — Dunwoodie decided on the brain, and specifically on brain cancer. A prior summer internship at the Van Andel Institute had spurred his interest in cancer research.
Fast-forward two years later to a January 2018 publication in the journal Oncotarget, Dunwoodie’s study is the first to describe glioblastoma-specific gene co-expression relationships among a group of 22 specific genes.
Heard in the news as the disease afflicting Sen. John McCain and Beau Biden, the late son of former Vice President Joe Biden, glioblastoma is highly malignant and is characterized by its lethality. Patients with glioblastoma have a median survival time of only 14.6 months after diagnosis.
“Like many other tumors, diseases and complex traits, glioblastoma is controlled by a variety of genetic and epigenetic factors,” Dunwoodie said. “If there was one master regulator of these cancers, we’d say, ‘We’re going to drug that and we’re going to save millions of lives every year,’ but there are more things going on in glioblastoma than we can presently identify.”
However, the complexity of glioblastoma is fitting for research in Feltus’ Systems Genetics Lab in Clemson’s department of genetics and biochemistry where Dunwoodie is a student. Systems genetics, as the lab’s name implies, uses computer- and mathematics-based approaches to analyze biological systems, such as genes and regulatory pathways.
To make his discovery, Dunwoodie first compiled data from two online public databases for genomic information: The Cancer Genome Atlas (TCGA) and the National Center for Biotechnology Information (NCBI).
From TCGA, Dunwoodie downloaded more than 2,000 tumor expression datasets, each one detailing how tumor cells differ from normal cells at the genetic level. Five different types of tumors, including those from bladder, ovarian, thyroid, lower-grade glioma and glioblastoma cancers, were included in the data to achieve a well-rounded case study.
He then organized the 2,000-plus datasets, each showing approximately 75,000 genes, into a gene expression matrix, a table that quantifies the expression level of each gene across every sample.
For example, one of the genes pulled from TCGA, called LAPTM5, encodes a protein that is involved in the formation of blood cells. In the gene expression matrix, LAPTM5 was assessed across each tumor type to gauge whether it is overly active (overexpressed) or underactive (underexpressed) in one tumor type versus another, indicated by a numerical ranking. He used the same scoring process for the 74,999 remaining genes across the five tumor types in the TCGA data.
Dunwoodie and Will Poehlman, a graduate student in the Systems Genetics Lab, created a separate gene expression matrix, encompassing 210,000 genes from 204 datasets from the NCBI database — including normal brain samples, glioblastoma brain samples and brain samples from patients with Parkinson’s disease — for comparison.
Using novel computer software developed by Feltus and former graduate student Stephen Ficklin, who is now an assistant professor at Washington State University, Dunwoodie was able to translate the matrices into two different gene co-expression networks, a visual representation of the data that provides insights into how the genes interact with one another.
The software package, known as Knowledge Independent Network Construction (KINC), is novel in that it finds expression relationships between genes without the researchers having to conduct any prior analyses. This knowledge-independent method reduces the amount of “noise” from laboratory protocols or from natural variation between cells that can prevent genetic interactions from being discovered.
“Through the two gene co-expression networks, we found a group of 22 genes that were co-expressed in a single module, both in The Cancer Genome Atlas network and in the NCBI brain network,” Dunwoodie said. “Only about 70 genes overlapped between the two networks, and 22 of them were in the same module — the same group of co-expressed genes. The overlap was really easy to spot.”
While it’s tempting to think that the genes, many of which function in the immune system, are feeding off one another to affect glioblastoma, Dunwoodie said this isn’t exactly the case.
“It’s hard to say that they’re working together, because these are correlations. So if person A runs eight miles on the same day that person B runs eight miles, it doesn’t necessarily mean that they’re running together,” Dunwoodie said. “It’s more likely that these genes are being regulated in the same way, and there are probably several things regulating them that we can’t currently identify.”
What’s more, these 22 genes, when compared between glioblastoma and noncancerous samples, were found to have much stronger co-expression levels in glioblastoma, suggesting a disease-specific regulatory mechanism. The same finding was uncovered when comparing glioblastoma to lower-grade glioma, a less aggressive type of brain cancer, indicating a glioblastoma-specific activity to the 22 genes.
The other notable finding of the study showed that the 22 genes are more associated with mesenchymal glioblastoma, a distinct subtype of the cancer, and that when the genes are highly expressed, they decrease survival time for patients in the mesenchymal group.
As is the case in research, where answering one question results in a plethora of new questions, the team’s study is just one step toward understanding glioblastoma pathogenesis.
“It would be nice to find out what the 22 genes are specifically doing,” Dunwoodie said. “Are they expressed in the surrounding immune cells? Are they a cause of cancer or are they an effect of cancer? Does cancer propagate their expression? Why these genes are co-expressed there and what they’re doing are questions that haven’t been answered.”
Dunwoodie, who plans to attend medical school to become a physician informaticist, says the tools and methods he learned in the Systems Genetics Lab will stick with him long into his career.
“Cancer research is interesting because there are so many amazing people doing so many amazing things, but this is just one drop in the bucket,” Dunwoodie said. “For me, the real purpose is patients being cured. Getting a paper published is great, but no one was immediately cured because of this, and that’s the ultimate goal.”